Консенсус экспертов Российского медицинского общества по артериальной гипертонии. Артериальная гипертония и приверженность к антигипертензивной терапии

   Несмотря на существующие рекомендации по диагностике и лечению артериальной гипертонии (АГ), широкий выбор антигипертензивных препаратов (АГП), эффективность лечения АГ сохраняется на низком уровне. Основной причиной неудовлетворительного контроля АГ является неприверженность пациентов к проводимому лечению, что негативно влияет на прогноз в отношении сердечно-сосудистых осложнений. Первым шагом в алгоритме повышения приверженности к антигипертензивной терапии (АГТ) является определение ее уровня. Существуют различные методы оценки приверженности, отличающиеся доступностью и точностью. Выделяют несколько категорий факторов, влияющих на уровень приверженности. Выявление причин у конкретного больного является значимым этапом на пути преодоления низкой приверженности к АГТ. Кроме того, необходимо использование стратегий по повышению уровня приверженности к АГТ, включающих как «упрощение» схемы лечения, так и укрепление взаимодействия врач-пациент.

   Целью данного консенсуса является обобщение и дополнение знаний о распространённости приверженности к АГТ у пациентов с АГ, методах оценки уровня приверженности, причинах низкой приверженности к лечению артериальной гипертонии, подходах к улучшению приверженности к приёму АГП.

1. Аксенова АВ, Ощепкова ЕВ, Чазова ИЕ. Лечение больных артериальной гипертонией в реальной клинической практике в 2010–2020 гг.(по данным национального регистра артериальной гипертонии). Терапевтический архив 2022;94:9–17. doi: 10.26442/00403660.2022.01.201318

2. Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: The NHANES III Linked Mortality Study. Sci Rep 2018;8:1–7. doi: 10.1038/s41598-018-27377-2

3. Muntner P, Hardy ST, Fine LJ, et al. Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018. JAMA 2020;324:1190. doi: 10.1001/jama.2020.14545

4. Балабанова Ю.А., Драпкина О.М., Куценко В.А., и др. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространённости, лечении и его эффективности. Данные исследования ЭССЕ-РФ3. Кардиоваскулярная терапия и профилактика 2023;22:3785. doi: 10.15829/1728-8800-2023-3785

5. Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021;398:957–80. doi: 10.1016/S0140-6736(21)01330-1

6. Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory hypertension: A novel phenotype of antihypertensive treatment failure. Hypertension 2016;67:1085–92. doi: 10.1161/HYPERTENSIONAHA.116.06587

7. Аксенова АВ, Сивакова ОА, Блинова НВ, и др. Консенсус экспертов Российского медицинского общества по артериальной гипертонии по диагностике и лечению резистентной артериальной гипертонии. Терапевтический архив 2021;93:1018–29. doi: 10.26442/00403660.2021.09.201007

8. Buhnerkempe MG, Botchway A, Prakash V, et al. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens 2019;37:1797–804. doi: 10.1097/HJH.0000000000002103

9. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125:1635–42. doi: 10.1161/CIRCULATIONAHA.111.068064

10. Chia R, Pandey A, Vongpatanasin W. Resistant hypertension-defining the scope of the problem. Prog Cardiovasc Dis 2020;63:46–50. doi: 10.1016/j.pcad.2019.12.006

11. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertensi. J Hypertens 2023;Publish Ah. doi: 10.1097/HJH.0000000000003480

12. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: Detection, evaluation, and management a scientific statement from the American Heart Association. vol. 72. 2018. doi: 10.1161/HYP.0000000000000084

13. Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension 2022;79:E1–14. doi: 10.1161/HYP.0000000000000203

14. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317–25. doi: 10.1046/j.1365-2796.1997.112133000.x

15. Chaudri NA. Adherence to long-term therapies evidence for action World Health Organization (WHO). Ann Saudi Med 2004;24:221–2. doi: 10.5144/0256-4947.2004.221

16. Bramley TJ, Nightengale BS, Frech-Tamas F, Gerbino PP. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006;12:239–45. doi: 10.18553/jmcp.2006.12.3.239

17. Dalli LL, Olaiya MT, Kim J, et al. Antihypertensive medication adherence and the risk of vascular events and falls after stroke: a real-world effectiveness study using linked registry data. Hypertension 2023;80:182–91. doi: 10.1161/HYPERTENSIONAHA.122.19883

18. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521–30. doi: 10.1097/01.mlr.0000163641.86870.af

19. Burnier M, Egan BM. Adherence in hypertension. Circ Res 2019;124:1124–40. doi: 10.1161/CIRCRESAHA.118.313220

20. Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary nonadherence to chronic disease medications: A meta-analysis. Patient Prefer Adherence 2018;12:721–31. doi: 10.2147/PPA.S161151

21. Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002;24:1347–57. doi: 10.1016/S0149-2918(02)80039-X

22. Gupta P, Patel P, Štrauch B, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension 2017;69:1113–20. doi: 10.1161/HYPERTENSIONAHA.116.08729

23. Hameed MA, Tebbit L, Jacques N, et al. Non-adherence to antihypertensive medication is very common among resistant hypertensives: Results of a directly observed therapy clinic. J Hum Hypertens 2016;30:83–9. doi: 10.1038/jhh.2015.38

24. Lauffenburger JC, Landon JE, Fischer MA. Effect of combination therapy on adherence among US patients initiating therapy for hypertension: a cohort study. J Gen Intern Med 2017;32:619–25. doi: 10.1007/s11606-016-3972-z

25. Tajeu GS, Kent ST, Kronish IM, et al. Trends in antihypertensive medication discontinuation and low adherence among medicare beneficiaries initiating treatment from 2007 to 2012. Hypertension 2016;68:565–75. doi: 10.1161/HYPERTENSIONAHA.116.07720

26. Tajeu GS, Kent ST, Huang L, et al. Antihypertensive Medication Nonpersistence and Low Adherence for Adults <65 Years Initiating Treatment in 2007-2014. Hypertension 2019;74:35–46. doi: 10.1161/HYPERTENSIONAHA.118.12495

27. Feng Y, Zhao Y, Yang X, et al. Adherence to antihypertensive medication and cardiovascular disease events in hypertensive patients: a dose–response meta-analysis of 2 769 700 participants in cohort study. QJM An Int J Med 2022;115:279–86. doi: 10.1093/qjmed/hcaa349

28. Burnier M. Drug adherence in hypertension. Pharmacol Res 2017;125:142–9. doi: 10.1016/j.phrs.2017.08.015

29. Schoenthaler A, Chaplin WF, Allegrante JP, et al. Provider communication effects medication adherence in hypertensive African Americans. Patient Educ Couns 2009;75:185–91. doi: 10.1016/j.pec.2008.09.018

30. Schoenthaler A, Knafl GJ, Fiscella K, Ogedegbe G. Addressing the social needs of hypertensive patients. Circ Cardiovasc Qual Outcomes 2017;10:e003659. doi: 10.1161/CIRCOUTCOMES.117.003659

31. Ali DH, Kiliç B, Hart HE, et al. Therapeutic inertia in the management of hypertension in primary care. J Hypertens 2021;39:1238–45. doi: 10.1097/HJH.0000000000002783

32. Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension 2018;72:846–53. doi: 10.1161/HYPERTENSIONAHA.118.11308

33. Guthrie B, Inkster M, Fahey T. Tackling therapeutic inertia: role of treatment data in quality indicators. BMJ 2007;335:542–4. doi: 10.1136/bmj.39259.400069.AD

34. Proia KK, Thota AB, Njie GJ, et al. Team-Based care and improved blood pressure control. Am J Prev Med 2014;47:86–99. doi: 10.1016/j.amepre.2014.03.004

35. Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012;59:1124–31. doi: 10.1161/HYPERTENSIONAHA.112.194167

36. Poulter NR, Borghi C, Parati G, et al. Medication adherence in hypertension. J Hypertens 2020;38:579–87. doi: 10.1097/HJH.0000000000002294

37. Christensen DB, Williams B, Goldberg HI, et al. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care 1997;35:1164–70. doi: 10.1097/00005650-199711000-00008

38. Солнцева Т.Д., Сивакова О.А., Аксёнова А.В., Чазова И.Е. Антигипертензивная терапия и приверженность к лечению у пациентов с неконтролируемой артериальной гипертонией. Евразийский кардиологический журнал 2023;1685:24–30. doi: 10.38109/2225-1685-2023-4-24-30

39. Xie L., Frech-Tamas F., Marrett E., Baser O. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin 2014;30:2415–22. doi: 10.1185/03007995.2014.964853

40. Jackson T, Wright J, Jeff D. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–16. doi: 10.1056/NEJMoa1511939

41. Dusing R, Weisser B, Mengden T. Changes in antihypertensive therapy – the role of adverse effects and compliance. Blood Press 1998;7:313–5. doi: 10.1080/080370598437187

42. Chambers JA, O’Carroll RE, Dennis M, et al. “My doctor has changed my pills without telling me”: impact of generic medication switches in stroke survivors. J Behav Med 2014;37:890–901. doi: 10.1007/s10865-013-9550-5

43. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728–40. doi: 10.18553/jmcp.2009.15.9.728

44. Gebreyohannes EA, Bhagavathula AS, Abebe TB, et al. Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital. Clin Hypertens 2019;25:1. doi: 10.1186/s40885-018-0104-6

45. Mancia G, Parodi A, Merlino L, Corrao G. Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. J Hypertens 2011;29:1012–8. doi: 10.1097/HJH.0b013e32834550d0

46. Jeong SM, Kim S, Wook Shin D, et al. Persistence and adherence to antihypertensive drugs in newly treated hypertensive patients according to initial prescription. Eur J Prev Cardiol 2021;28:E1–4. doi: 10.1177/2047487319900326

47. Corrao G, Soranna D, Merlino L, Mancia G. Similarity between generic and brand‐name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population‐based study. Eur J Clin Invest 2014;44:933–9. doi: 10.1111/eci.12326

48. Lee H, Yano Y, Cho SMJ, H et al. Adherence to antihypertensive medication and incident cardiovascular events in young adults with hypertension. Hypertension 2021;77:1341–9. doi: 10.1161/HYPERTENSIONAHA.120.16784

49. Hamrahian SM, Maarouf OH, Fülöp T. A critical review of medication adherence in hypertension: barriers and facilitators clinicians should consider. Patient Prefer Adherence 2022;16:2749–57. doi: 10.2147/PPA.S368784

50. Simpson J, Jackson CE, Haig C, Jhund PS, Tomaszewski M, Gardner RS, и др. Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography–tandem mass spectrometry-based urine analysis. Eur Hear J – Cardiovasc Pharmacother 2021;7:296–301. doi: 10.1093/ehjcvp/pvaa071

51. Morrison VL, Holmes EAF, Parveen S, et al. Predictors of self-reported adherence to antihypertensive medicines: a multinational, cross-sectional survey. Value Heal 2015;18:206–16. doi: 10.1016/j.jval.2014.12.013

52. Mancia G, Zambon A, Soranna D, et al. Factors involved in the discontinuation of antihypertensive drug therapy. J Hypertens 2014;32:1708–16. doi: 10.1097/HJH.0000000000000222

53. Delara M, Murray L, Jafari B, et al. Prevalence and factors associated with polypharmacy : a systematic review and meta-analysis. BMC Geriatr 2022;22:601. doi: 10.1186/s12877-022-03279-x

54. Eze-Nliam CM, Thombs BD, Lima BB, et al. The association of depression with adherence to antihypertensive medications : a systematic review. J Hypertens 2010;28:1785–95. doi: 10.1097/HJH.0b013e32833b4a6f

55. Liu Q, Wang H, Liu A, et al. Adherence to prescribed antihypertensive medication among patients with depression in the United States. BMC Psychiatry 2022;22:764. doi: 10.1186/s12888-022-04424-x

56. Остроумова ОД, Парфенов ВА, Остроумова ТМ, Яхно НН, Чазова ИЕ, Боголепова АН, и др. Консенсус экспертов. Влияние антигипертензивной терапии на когнитивные функции. Системные гипертензии 2021;18:5–12. doi: 10.26442/2075082X.2021.1.200575

57. Bokhour BG, Kressin NR. What Is in a Name? Circ Cardiovasc Qual Outcomes 2015;8:452–4. doi: 10.1161/CIRCOUTCOMES.114.001662

58. Yadav AK, Budhathoki SS, Paudel M, et al. Patients understanding of their diagnosis and treatment plans during discharge in emergency ward in a tertiary care centre: A qualitative study. J Nepal Med Assoc 2019;57:357–60. doi: 10.31729/jnma.4639

59. Axon RN, Bradford WD, Egan BM. The role of individual time preferences in health behaviors among hypertensive adults: a pilot study. J Am Soc Hypertens 2009;3:35–41. doi: 10.1016/j.jash.2008.08.005

60. Bradford WD. The association between individual time preferences and health maintenance habits. Med Decis Mak 2010;30:99–112. doi: 10.1177/0272989X09342276

61. Наумова ЕА, Семенова ОН. Современный взгляд на проблему приверженности пациентов к длительному лечению. Кардиология: новости, мнения, обучение 2016;2:30–9.

62. Krousel‐Wood MA, Muntner P, Joyce CJ, et al. Adverse effects of complementary and alternative medicine on antihypertensive medication adherence: findings from the cohort study of medication adherence among older adults. J Am Geriatr Soc 2010;58:54–61. doi: 10.1111/j.1532-5415.2009.02639.x

63. Shen B, Guan T, Du X, et al. Medication adherence and perceived social support of hypertensive patients in China: a community-Based Survey Study. Patient Prefer Adherence 2022;Volume 16:1257–68. doi: 10.2147/PPA.S363148

64. Steiner JF, Ho PM, Beaty BL, et al. Sociodemographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circ Cardiovasc Qual Outcomes 2009;2:451–7. doi: 10.1161/CIRCOUTCOMES.108.841635

65. Bhusal L, Deep Pathak B, Dhakal B, et al. Determination of level of self‐reported adherence of antihypertensive drug(s) and its associated factors among patient with hypertension at a tertiary care center. J Clin Hypertens 2022;24:1444–50. doi: 10.1111/jch.14592

66. Pan J, Wu L, Wang H, et al. Determinants of hypertension treatment adherence among a Chinese population using the therapeutic adherence scale for hypertensive patients. Medicine (Baltimore) 2019;98:e16116. doi: 10.1097/MD.0000000000016116

67. Li S-C. Factors affecting therapeutic compliance: A review from the patients perspective. Ther Clin Risk Manag 2008;Volume 4:269–86. doi: 10.2147/TCRM.S1458

68. Бочкарева ЕВ, Бутина ЕК, Ким ИВ, Концевая АВ, Драпкина ОМ. Приверженность к антигипертензивной терапии: систематический обзор российских проспективных исследований с 2000 по 2019 гг. Рациональная Фармакотерапия в Кардиологии 2020;16:770–9. doi: 10.20996/1819-6446-2020-10-20

69. Iihara N, Tsukamoto T, Morita S, et al. Beliefs of chronically ill Japanese patients that lead to intentional non-adherence to medication. J Clin Pharm Ther 2004;29:417–24. doi: 10.1111/j.1365-2710.2004.00580.x

70. Shahin W, Kennedy GA, Stupans I. The association between social support and medication adherence in patients with hypertension: A systematic review. Pharm Pract (Granada) 2021;19:2300. doi: 10.18549/PharmPract.2021.2.2300

71. Huang T, Bai L, Wushouer H, et al. Clinical outcome and medical cost of originator and generic antihypertensive drugs: a population-based study in Yinzhou, China. Front Pharmacol 2022;13:1–9. doi: 10.3389/fphar.2022.757398

72. Conn VS, Ruppar TM, Chase JAD, et al. Interventions to improve medication adherence in hypertensive patients : systematic review and meta-analysis. Curr Hypertens Rep 2015;17:1–15. doi: 10.1007/s11906-015-0606-5

73. Pan J, Hu B, Wu L, Li Y. The Effect of Social Support on Treatment Adherence in Hypertension in China. Patient Prefer Adherence 2021;Volume 15:1953–61. doi: 10.2147/PPA.S325793

74. Londoño Agudelo E, Battaglioli T, Díaz Piñera A, et al. Effectiveness of a provider and patient-focused intervention to improve hypertension management and control in the primary health care setting in Cuba: a controlled before-after study. BMC Prim Care 2023;24:10. doi: 10.1186/s12875-022-01959-6

75. Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Reports 2019 Apr;92(2):117-122. doi: 10.15386/mpr-1201

76. Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int 2015;2015:1–12. doi: 10.1155/2015/217047

77. Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res 2012;12:270. doi: 10.1186/1472-6963-12-270

78. Inui TS. Improved outcomes in hypertension after physician tutorials. Ann Intern Med 1976;84:646. doi: 10.7326/0003-4819-84-6-646

79. Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2010 Mar 17:(3):CD005182. doi: 10.1002/14651858.CD005182.pub4

80. Nguyen T-M-U, Caze A La, Cottrell N. What are validated self-report adherence scales really measuring? : a systematic review. Br J Clin Pharmacol 2014;77:427–45. doi: 10.1111/bcp.12194

81. Hamdidouche I, Jullien V, Boutouyrie P, et al. Drug adherence in hypertension: from methodological issues to cardiovascular outcomes. J Hypertens 2017;35:1133–44. doi: 10.1097/HJH.0000000000001299

82. Pareja-Martínez E, Esquivel-Prados E, Martínez-Martínez F, García-Corpas JP. Questionnaires on adherence to antihypertensive treatment : a systematic review of published questionnaires and their psychometric properties. Int J Clin Pharm 2020;42:355–65. doi: 10.1007/s11096-020-00981-x

83. Glasser SP, Vitolins M, Rocco MV, et al. Is medication adherence predictive of cardiovascular outcomes and blood pressure control? The systolic blood pressure intervention trial (SPRINT). Am J Hypertens 2022;35:182–91. doi: 10.1093/ajh/hpab145

84. Hamdidouche I, Jullien V, Boutouyrie P, et al. Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients. J Hypertens 2017;35:1891–8. doi: 10.1097/HJH.0000000000001402

85. Hamilton GA. Measuring adherence in a hypertension clinical trial. Eur J Cardiovasc Nurs 2003;2:219–28. doi: 10.1016/S1474-5151(03)00058-6

86. Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood Press 2001;10:62–73. doi: 10.1080/08037050152112041

87. Wetzels G, Nelemans P, Schouten J, et al. Electronic monitoring of adherence as a tool to improve blood pressure control a randomized controlled trial. Am J Hypertens 2007;20:119–25. doi: 10.1016/j.amjhyper.2006.07.018

88. Christensen A, Osterberg LG, Hansen EH. Electronic monitoring of patient adherence to oral antihypertensive medical treatment: a systematic review. J Hypertens 2009;27:1540–51. doi: 10.1097/HJH.0b013e32832d50ef

89. Hafezi H, Robertson TL, Moon GD, et al. An ingestible sensor for measuring medication adherence. IEEE Trans Biomed Eng 2015;62:99–109. doi: 10.1109/TBME.2014.2341272

90. Naik R, Macey N, West RG, et al. First use of an ingestible sensor to manage uncontrolled blood pressure in primary practice: the UK hypertension registry. J Community Med Health Educ January 2017;7(1). doi: 10.4172/2161-0711.1000506

91. Hjørnholm U, Aamodt M, Larstorp AC, et al. Directly observed therapy in hypertension (DOT-HTN), 2018:57–85. doi: 10.1007/978-3-319-76593-8_6

92. Banegas JR, Segura J, Ruilope LM, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004;43:1338–44. doi: 10.1161/01.HYP.0000127424.59774.84

93. Peeters LEJ, Feyz L, Boersma E, et al. Clinical applicability of monitoring antihypertensive drug levels in blood. Hypertension 2020;76:80–6. doi: 10.1161/HYPERTENSIONAHA.120.15038

94. Štrauch B, Petrák O, Zelinka T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013;31:2455–61. doi: 10.1097/HJH.0b013e3283652c61

95. Hamdidouche I, Jullien V, Boutouyrie P, et al. Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients. J Hypertens 2017;35:1891–8. doi: 10.1097/HJH.0000000000001402.

96. Sutherland JJ, Morrison RD, McNaughton CD, et al. Assessment of patient medication adherence, medical record accuracy, and medication blood concentrations for prescription and over-the-counter medications. JAMA Netw open 2018;1:e184196. doi: 10.1001/jamanetworkopen.2018.4196.

97. Gupta P, Patel P, Horne R, et al. How to screen for non-adherence to antihypertensive therapy. Curr Hypertens Rep 2016;18:89. doi: 10.1007/s11906-016-0697-7

98. Агеев ФТ, Смирнова МД, Фофанова ТВ. Повышение приверженности к терапии: «дело техники»? Сердечная недостаточность 2011;4:238–43. doi: 10.1002/14651858.CD000011.pub4

99. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014;2014. doi: 10.1002/14651858.CD000011.pub4

100. Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension 2022;79. doi: 10.1161/HYP.0000000000000203

101. Stergiou G, Brunström M, MacDonald T, et al. Bedtime dosing of antihypertensive medications : systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. J Hypertens 2022;40:1847–58. doi: 10.1097/HJH.0000000000003240

102. Wallbach M, Lach N, Stock J, et al. Direct assessment of adherence and drug interactions in patients with hypertensive crisis—a cross-sectional study in the Emergency Department. J Clin Hypertens 2019;21:55–63. doi: 10.1111/jch.13448

103. Kulkarni S, Rao R, Goodman JDH, et al. Nonadherence to antihypertensive medications amongst patients with uncontrolled hypertension. Medicine (Baltimore) 2021;100:e24654. doi: 10.1097/MD.0000000000024654

104. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296–310. doi: 10.1016/S0149-2918(01)80109-0

105. Parati G, Kjeldsen S, Coca A, et al. Adherence to single-pill versus free-equivalent combination therapy in hypertension. Hypertension 2021;77:692–705. doi: 10.1161/HYPERTENSIONAHA.120.15781

106. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension 2010;55:399–407. doi: 10.1161/HYPERTENSIONAHA.109.139816

107. Rea F, Savaré L, Franchi M, et al. Adherence to treatment by initial antihypertensive mono and combination therapies. Am J Hypertens 2021;34:1083–91. doi: 10.1093/ajh/hpab083

108. Tsioufis K, Kreutz R, Sykara G, et al. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. J Hypertens 2020;38:1016–28. doi: 10.1097/HJH.0000000000002381

109. Bramlage P, Schmidt S, Sims H. Fixed‐dose vs free‐dose combinations for the management of hypertension — an analysis of 81 958 patients. J Clin Hypertens 2018;20:705–15. doi: 10.1111/jch.13240

110. Чазова И.Е., Жернакова Ю.В. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии 2019;16:6–31. doi: 10.26442/2075082X.2019.1.190179

111. Артериальная гипертензия у взрослых. Клинические рекомендации 2022 2022:1–161.

112. Кисляк ОА, Жернакова ЮВ, Аксенова АВ, Чазова ИЕ. Консенсус экспертов Российского медицинского общества по артериальной гипертонии: применение фиксированных комбинаций в лечении больных артериальной гипертонией. Системные гипертензии 2024;21:5–13. doi: 10.38109/2075-082X-2024-1-5-13

113. Карпов ЮА, Горбунов ВМ, Логунова НА. Применение тройной фиксированной комбинации в лечении артериальной гипертензии — возможность эффективного контроля артериального давления при использовании комбинированной антигипертензивной терапии: основные результаты Российского наблюдательного исследования. Российский кардиологический журнал 2020;25:4130. doi: 10.15829/1560-4071-2020-4130

114. Du L, Cheng Z, Zhang Y, et al. The impact of fixed‐dose combination versus free‐equivalent combination therapies on adherence for hypertension: a meta‐analysis. J Clin Hypertens 2018;20:902–7. doi: 10.1111/jch.13272

115. Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens 2011;13:898–909. doi: 10.1111/j.1751-7176.2011.00550.x

116. Miranda RD, Mion D, Rocha JC, et al. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: The assessment of combination therapy of amlodipine/ramipril (ATAR) study. Clin Ther 2008;30:1618–28. doi: 10.1016/j.clinthera.2008.09.008

117. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21:220–4. doi: 10.1038/sj.jhh.1002140

118. Марцевич СЮ, Кутишенко НП, Лукина ЮВ, Драпкина ОМ. Полифармация: определение, влияние на исходы,необходимость коррекции. Рациональная фармакотерапия в кардиологии 2023;19:254–63. doi: 10.20996/1819-6446-2023-2924

119. Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387:967–77. doi: 10.1056/NEJMoa2208275

120. Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence. J Am Coll Cardiol 2014;64:2071–82. doi: 10.1016/j.jacc.2014.08.021

121. Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014;348:g3318–g3318. doi: 10.1136/bmj.g3318

122. Thom S. Effects of a fixed-dose combination strategy on aadherence and risk factors in patients with or at high risk of CVD. JAMA 2013;310:918. doi: 10.1001/jama.2013.277064

123. Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 2021;398:1133–46. doi: 10.1016/S0140-6736(21)01827-4

124. Mahmood S, Jalal Z, Abdul Hadi M, et al. Non-adherence to prescribed antihypertensives in primary, secondary and tertiary healthcare settings in islamabad, Pakistan: a cross-sectional study. Patient Prefer Adherence 2020;Volume 14:73–85. doi: 10.2147/PPA.S235517

125. Law MR. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427–0. doi: 10.1136/bmj.326.7404.1427

126. Алексеева ТА, Литвин АЮ, Елфимова ЕМ, и др. Consensus of experts from the Russian Medical Society of Arterial Hypertension. Arterial hypertension and erectile dysfunction. Системные гипертензии 2021;18:69–79. doi: 10.26442/2075082X.2021.2.200836

127. Akasaki Y, Kubozono T, Higuchi K, Ohishi M. Relationships between anti-hypertensive drugs and nocturia : a systematic review. J Hypertens 2021;39:e48. doi: 10.1097/01.hjh.0000744868.03766.48

128. Liang L, Kung JY, Mitchelmore B, et al. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment : a systematic review and network meta‐analysis. J Clin Hypertens 2022;24:536–54. doi: 10.1111/jch.14436

129. Fusco N, Sils B, Graff JS, et al. Cost-sharing and adherence, clinical outcomes, health care utilization, and costs : a systematic literature review. J Manag Care Spec Pharm 2023;29:4–16. doi: 10.18553/jmcp.2022.21270

130. Cooper-DeHoff RM, Elliott WJ. Generic drugs for hypertension: Are they really equivalent? Curr Hypertens Rep 2013;15:340–5. doi: 10.1007/s11906-013-0353-4

131. Dinic M, Maillard N, Bouillet M, et al. Generic vs. brand-name drugs for the treatment of hypertension. Arch Cardiovasc Dis Suppl 2019;11:e373. doi: 10.1016/j.acvdsp.2019.05.100

132. Corrao G, Soranna D, La Vecchia C, et al. Medication persistence and the use of generic and brandname blood pressure-lowering agents. J Hypertens 2014;32:1146–53. doi: 10.1097/HJH.0000000000000130

133. Ryan D, Carr A. A study of the differential effects of Tomm’s questioning styles on therapeutic alliance. Fam Process 2001;40:67–77. doi: 10.1111/j.1545-5300.2001.4010100067.x

134. Thakkar J, Kurup R, Laba T-L, et al. Mobile telephone text messaging for medication adherence in chronic disease. JAMA Intern Med 2016;176:340. doi: 10.1001/jamainternmed.2015.7667

135. Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю., и др. Методические рекомендации: «Приверженность к лекарственной терапии у больных хроническими неинфекционными заболеваниями. Решение проблемы в ряде клинических ситуаций». Профилактическая Медицина 2020;23(3):2042-2060. doi: 10.17116/profmed20202303242

136. Фофанова ТВ, Агеев ФТ, Смирнова МД, Деев АД. Приверженность к терапии в амбулаторных условиях: возможность выявления и оценка эффективности терапии. Кардиология 2017;57:35–42. doi: 10.18087/cardio.2017.7.10004

137. Агеев Ф.Т., Фофанова Т.В., Смирнова М.Д., и др. Методы технического воздействия как фактор повышения приверженности терапии больных сердечно-сосудистыми заболеваниями в амбулаторной практике. Итоги годичного наблюдения. Кардиоваскулярная терапия и профилактика 2012;11:36–41. doi: 10.15829/1728-8800-2012-4-36-41

138. Fletcher BR, Hartmann-Boyce J, Hinton L, McManus RJ. The effect of self-monitoring of blood pressure on medication adherence and ifestyle factors: a systematic review and meta-analysis. Am J Hypertens 2015;28:1209–21. doi: 10.1093/ajh/hpv008

139. Stergiou GS, Palatini P, Parati G, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens 2021;39:1293–302. doi: 10.1097/HJH.0000000000002843

140. Солнцева Т.Д., Сивакова О.А., Чазова И.Е. От пальпации пульса до безманжетного измерения: эволюция способов определения артериального давления. Терапевтический архив 2021;93:526–31. doi: 10.26442/00403660.2021.04.200690

141. Бойцов СА, Иванова ГЕ, Рогоза АН, и др. Анализ методов и технических решений для измерения артериального давления с применением телемедицинских технологий при кардиологических исследованиях в процессе медицинской реабилитации. Вестник воостановительной медицины 2018;6:91–5.

142. Schneider MP, Burnier M. Partnership between patients and interprofessional healthcare providers along the multifaceted journey to medication adherence. Br J Clin Pharmacol 2023;89:1992–5. doi: 10.1111/bcp.15325

143. Fuller RH, Perel P, Navarro-Ruan T, et al. Improving medication adherence in patients with cardiovascular disease : a systematic review. Heart 2018;104:1238–43. doi: 10.1136/heartjnl-2017-312571

144. Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control. Am J Prev Med 2014;47:86–99. doi: 10.1016/j.amepre.2014.03.004

145. Baker D, Roberts D, Newcombe R, Fox K. Evaluation of drug information for cardiology patients. Br J Clin Pharmacol 1991;31:525–31. doi: 10.1111/j.1365-2125.1991.tb05574.x

146. Ukoha-Kalu BO, Isah A, Biambo AA, et al. Effectiveness of educational interventions on hypertensive patients’ self-management behaviours: an umbrella review protocol. BMJ Open 2023;13:e073682. doi: 10.1136/bmjopen-2023-073682

147. Чазова И.Е., Агеев Ф.Т., Фофанова Т.В., и др. Обучение и самообразование пациента – важный шаг на пути повышения приверженности пациента лечению. Системные гипертензии 2014;3:7–10.

148. Naik AD, Kallen MA, Walder A, Street RL. Improving hypertension control in diabetes mellitus. Circulation 2008;117:1361–8. doi: 10.1161/CIRCULATIONAHA.107.724005

149. Lindenfeld J, Jessup M. ‘Drugs don’t work in patients who don’t take them’ (C. Everett Koop, MD, US Surgeon General, 1985). Eur J Heart Fail 2017;19:1412–3. doi: 10.1002/ejhf.920